共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bioactive extracellular matrix scaffolds engineered with proangiogenic proteoglycan mimetics and loaded with endothelial progenitor cells promote neovascularization and diabetic wound healing显示文摘Diabetic ischemic wound treatment remains a critical clinical challenge.Neovascularization plays a significant role in wound healing during all stages of the tissue repair process.Strategies that enhance angiogenesis and neovascularization and improve ischemic pathology may promote the healing of poor wounds,particularly diabetic wounds in highly ischemic conditions.We previously identified a cyclic peptide LXW7 that specifically binds to integrinαvβ3 on endothelial progenitor cells(EPCs)and endothelial cells(ECs),activates vascular endothelial growth factor(VEGF)receptors,and promotes EC growth and maturation.In this study,we designed and synthesized a multi-functional pro-angiogenic molecule by grafting LXW7 and collagen-binding peptides(SILY)to a dermatan sulfate(DS)glycosaminoglycan backbone,named LXW7-DS-SILY,and further employed this multi-functional molecule to functionalize collagen-based extracellular matrix(ECM)scaffolds.We confirmed that LXW7-DS-SILY modification significantly promoted EPC attachment and growth on the ECM scaffolds in vitro and supported EPC survival in vivo in the ischemic environment.When applied in an established Zucker Diabetic Fatty(ZDF)rat ischemic skin flap model,LXW7-DS-SILY-functionalized ECM scaffolds loaded with EPCs significantly improved wound healing,enhanced neovascularization and modulated collagen fibrillogenesis in the ischemic environment.Altogether,this study provides a promising novel treatment to accelerate diabetic ischemic wound healing,thereby reducing limb amputation and mortality of diabetic patients. | Siqi He Tanaya Walimbe Hongyuan Chen Kewa Gao Priyadarsini Kumar Yifan Wei Dake Hao Ruiwu Liu Diana L.Farmer Kit S.Lam Jianda Zhou Alyssa Panitch Aijun Wang | 2022 | Bioactive Materials2022，7，4： | 2 |
| 2 | 缺血性心脏病患者接受骨髓单个核细胞移植治疗方案的临床研究显示文摘目的探究缺血性心脏病患者接受骨髓单个核细胞移植治疗方案的临床效果。方法择选该院2016年1月—2019年1月收治的经冠状动脉造影确诊冠心病患者40例为研究对象,按随机分组原则由计算机分组工具,自动均分为研究组和对照组,每组20例。治疗后,分别就两组患者的超声指标和心肌灌注缺损区面积变化情况实施对比,评价两种方法的疗效。结果治疗后,研究组患者LVEDV(101.5±7.1)mL、LVESV(56.3±5.8)mL、LVEF(43.8±5.7)%优于对照组的(106.3±8.8)mL、(61.7±6.7)mL、(56.3±5.9)%,差异有统计学意义(t=2.198、2.725、6.814,P<0.05);研究组患者心肌灌注缺损面积(15.2±6.3)%多于对照组(21.4±6.7)%,差异有统计学有意义(t=3.014,P<0.05)。结论缺血性心脏病患者行骨髓单个核细胞移植治疗,疗效较为显著,有利于患者左室收缩功能的改善,且安全性良好,具有较高的应用价值。 | 回艳平 | 2021 | 世界复合医学2021，7，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员